Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Tran HT, et al. Among authors: madden t. Cancer Chemother Pharmacol. 2004 Oct;54(4):308-14. doi: 10.1007/s00280-004-0816-z. Epub 2004 Jun 4. Cancer Chemother Pharmacol. 2004. PMID: 15184994 Clinical Trial.
Phase I study of recombinant human endostatin in patients with advanced solid tumors.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Herbst RS, et al. Among authors: madden t. J Clin Oncol. 2002 Sep 15;20(18):3792-803. doi: 10.1200/JCO.2002.11.061. J Clin Oncol. 2002. PMID: 12228199 Clinical Trial.
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Andersson BS, et al. Among authors: madden t. Biol Blood Marrow Transplant. 2002;8(9):477-85. doi: 10.1053/bbmt.2002.v8.pm12374452. Biol Blood Marrow Transplant. 2002. PMID: 12374452 Free article. Clinical Trial.
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW. Tran HT, et al. Among authors: madden t. Bone Marrow Transplant. 2000 Sep;26(5):463-70. doi: 10.1038/sj.bmt.1702561. Bone Marrow Transplant. 2000. PMID: 11019834
Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW. Tran H, et al. Among authors: madden t. Biol Blood Marrow Transplant. 2004 Nov;10(11):805-12. doi: 10.1016/j.bbmt.2004.07.010. Biol Blood Marrow Transplant. 2004. PMID: 15505611 Free article.
428 results